Buy Like Buffett
Watchlist

STAAR SURGICAL CO

STAA · Healthcare · $1.2B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat
Share / Embed this score
Embed this score

The five investor questions

32

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $230M to $239M, increasing; diluted EPS 0.56 to -1.62, decreasing.

70

Median gross margin 171.8% over 10y, variable.

35

Median ROIC 9.9%, above the 12% hurdle in 40% of years.

55

Net cash position — no leverage risk.

24

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
387% above value if growth stopped today
$21.3M
$4.80
$4.80
$23.38
387% above value if growth stopped today

What today’s price assumes: owner earnings growing ~37%/yr over 5 years. The zero-growth estimate assumes owner earnings stay flat (0% growth).

How to read this

We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.

Score records captured Jul 26, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY

Missing a usable price or zero-growth estimate: ANF, BKNG.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

18 years of fundamentals

The business, in plain English

STAAR SURGICAL CO booked $239M of revenue in FY2025 in the Healthcare sector and kept 76.2% of it as gross profit — a high-margin business by that measure. After every other cost, −33.6% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $51.1M (FY2009) to $239M (FY2025) — about 10.1% a year compounded over 16 years.

It earned −37.9% on invested capital in the latest filed year, FY2025. Across the full 17-year measurable filed record, median ROIC was −3.9%. Over the v3 recent window (10 measurable filed years), median ROIC was 9.9%. The Returns on Capital filter above scores it 35/100.

STAA's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Pricing Power is the strongest of the five filters (70/100) and Capital Allocation the weakest (24/100), which is how STAA lands at 43/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2008–FY2025 · 18 fiscal years, normalized from STAA’s SEC filings

Sales, as filed$239M FY2025
$0$200M2008201420202025
Revenue kept after cost of goods76.2% FY2025
0%200%400%2008201420202025
Standard ROIC or separately labeled Operating ROICROIC −37.9% FY2025
0%50%2008201420202025
Cash an owner could take out−$77.9M FY2025
−$50M$02008201420202025

Gaps in a line mean that item isn’t in STAA’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How STAAR SURGICAL CO makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$239M · 100%Cost of revenue$57M · 24%Gross profit$182M · 76%Operating income−$91.7M · −38%Income before tax−$82.3M · −34%Income tax−$1.8M · −1%Net income−$80.4M · −34%As of 2026-01-02 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$239M100%
Cost of revenue$57M24%
$182M76%
−$91.7M−38%
Income before tax−$82.3M−34%
Income tax−$1.8M−1%
−$80.4M−34%
Source: · event Jan 2, 2026 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

What STAAR SURGICAL CO owns — and owes

STAAR SURGICAL CO's filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$452M100%
Cash and equivalents$153M34%
Stockholders’ equity$344M76%
Source: · event Jan 2, 2026 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What drives STAAR SURGICAL CO’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−22%Tax burden98%net income ÷ pretax incomeInterest burden90%pretax ÷ operating incomeOperating margin−38%operating income ÷ revenueAsset turnover0.50×revenue ÷ average assetsEquity multiplier1.30×average assets ÷ average equityAs of 2026-01-02 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$80.4MFY2025
Income before tax−$82.3MFY2025
Operating income−$91.7MFY2025
$239MFY2025
Ending assets$452MFY2025
Beginning assets$510MFY2024
$344MFY2025
$397MFY2024
Source:
  • SEC filingFiling detailsAccession 0000718937-26-000004
· event Jan 2, 2026 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where STAAR SURGICAL CO's cash went

STAAR SURGICAL CO’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations−$34.2M−100%
Depreciation and amortization$8.3M24%
Source: · event Jan 2, 2026 · retrieved Jul 26, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding STAAR SURGICAL CO

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 unavailable

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Abrams CapitalUnavailableComparison unavailableFiling unavailable
Akre CapitalUnavailableComparison unavailableFiling unavailable
Baupost GroupUnavailableComparison unavailableFiling unavailable
Berkshire HathawayUnavailableComparison unavailableFiling unavailable
Brave Warrior AdvisorsUnavailableComparison unavailableFiling unavailable
Dodge & CoxUnavailableComparison unavailableFiling unavailable
First EagleUnavailableComparison unavailableFiling unavailable
FundsmithUnavailableComparison unavailableFiling unavailable
Gardner Russo & QuinnUnavailableComparison unavailableFiling unavailable
Gates Foundation TrustUnavailableComparison unavailableFiling unavailable
Mairs & PowerUnavailableComparison unavailableFiling unavailable
Markel / Markel-GaynerUnavailableComparison unavailableFiling unavailable
Oakmark / Harris AssociatesUnavailableComparison unavailableFiling unavailable
Pershing SquareUnavailableComparison unavailableFiling unavailable
Polen CapitalUnavailableComparison unavailableFiling unavailable
Sequoia / Ruane CunniffUnavailableComparison unavailableFiling unavailable
Southeastern Asset ManagementUnavailableComparison unavailableFiling unavailable
Tweedy, BrowneUnavailableComparison unavailableFiling unavailable
Yacktman Asset ManagementUnavailableComparison unavailableFiling unavailable

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source unavailable · event Jun 30, 2026 · retrieved Jul 26, 2026

Flagship explainer

What STAAR SURGICAL CO insiders reported

Insider activity is unavailable from the source; no zero-activity claim is shown.

Unavailable: Form 4 activity could not be retrieved for this rendering.

Moat Score history

16 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale43.2 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for STAA.

Healthcare context

#276 of 710 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #274MGRX MANGOCEUTICALS, INC.43.4Shallow moat
  2. #275STXS Stereotaxis, Inc.43.3Shallow moat
  3. #277PCYN PROCYON CORPORATION43.2Shallow moat
  4. #278STIM NEURONETICS, INC.43.2Shallow moat

Compare STAA with its nearest peers →All Healthcare companies on the Index →

Common questions about STAA

Does STAAR SURGICAL CO have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores STAAR SURGICAL CO (STAA) 43.2 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 32, pricing power 70, returns on capital 35, balance-sheet safety 55, capital allocation 24.
Is STAA trading below the conservative owner-earnings estimate?
The value if growth stopped today — a zero-growth baseline — is $4.80 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $23.38, that is 387% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has STAA's Moat Score changed over time?
The record logs 16 readings since Jul 17, 2026; the latest reads 43.2 out of 100 (shallow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell STAA. See the disclaimer.